These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27474395)

  • 1. Radiogenomics Monitoring in Breast Cancer Identifies Metabolism and Immune Checkpoints as Early Actionable Mechanisms of Resistance to Anti-angiogenic Treatment.
    Mehta S; Hughes NP; Li S; Jubb A; Adams R; Lord S; Koumakis L; van Stiphout R; Padhani A; Makris A; Buffa FM; Harris AL
    EBioMedicine; 2016 Aug; 10():109-16. PubMed ID: 27474395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.
    Labanca V; Bertolini F
    EBioMedicine; 2016 Aug; 10():13-4. PubMed ID: 27506898
    [No Abstract]   [Full Text] [Related]  

  • 3. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
    Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
    Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
    [No Abstract]   [Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor therapy in breast cancer: Molecular pathway, potential targets, and current treatment strategies.
    Zhang M; Liu J; Liu G; Xing Z; Jia Z; Li J; Wang W; Wang J; Qin L; Wang X; Wang X
    Cancer Lett; 2021 Nov; 520():422-433. PubMed ID: 34389434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenic role of miR-20a in breast cancer.
    Luengo-Gil G; Gonzalez-Billalabeitia E; Perez-Henarejos SA; Navarro Manzano E; Chaves-Benito A; Garcia-Martinez E; Garcia-Garre E; Vicente V; Ayala de la Peña F
    PLoS One; 2018; 13(4):e0194638. PubMed ID: 29617404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
    Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
    Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
    Simone V; Brunetti O; Lupo L; Testini M; Maiorano E; Simone M; Longo V; Rolfo C; Peeters M; Scarpa A; Azzariti A; Russo A; Ribatti D; Silvestris N
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-vascular endothelial growth factor therapy in breast cancer.
    Kristensen TB; Knutsson ML; Wehland M; Laursen BE; Grimm D; Warnke E; Magnusson NE
    Int J Mol Sci; 2014 Dec; 15(12):23024-41. PubMed ID: 25514409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
    Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
    Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.
    Trédan O; Lacroix-Triki M; Guiu S; Mouret-Reynier MA; Barrière J; Bidard FC; Braccini AL; Mir O; Villanueva C; Barthélémy P
    Target Oncol; 2015 Jun; 10(2):189-98. PubMed ID: 25185646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.
    Baker LCJ; Boult JKR; Thomas M; Koehler A; Nayak T; Tessier J; Ooi CH; Birzele F; Belousov A; Zajac M; Horn C; LeFave C; Robinson SP
    Br J Cancer; 2016 Sep; 115(6):691-702. PubMed ID: 27529514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
    Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
    Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
    Yopp AC; Schwartz LH; Kemeny N; Gultekin DH; Gönen M; Bamboat Z; Shia J; Haviland D; D'Angelica MI; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR
    Ann Surg Oncol; 2011 Aug; 18(8):2192-9. PubMed ID: 21286939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
    Gu JW; Young E; Busby B; Covington J; Johnson JW
    Cancer Biol Ther; 2009 Mar; 8(6):514-21. PubMed ID: 19242105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
    Baar J; Silverman P; Lyons J; Fu P; Abdul-Karim F; Ziats N; Wasman J; Hartman P; Jesberger J; Dumadag L; Hohler E; Leeming R; Shenk R; Chen H; McCrae K; Dowlati A; Remick SC; Overmoyer B
    Clin Cancer Res; 2009 May; 15(10):3583-90. PubMed ID: 19417018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression.
    Goto H; Nishioka Y
    Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29286323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
    Seeber A; Gunsilius E; Gastl G; Pircher A
    Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis as a therapeutic target in breast cancer.
    Koutras AK; Starakis I; Lymperatou D; Kalofonos HP
    Mini Rev Med Chem; 2012 Oct; 12(12):1230-8. PubMed ID: 22512568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.